Blood test may predict kidney cancer drug response
NCT ID NCT03185039
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at two substances in the blood, called MMP2 and MMP9, to see if they can predict how well certain drugs work for people with advanced kidney cancer. Researchers will measure these markers in 50 patients who are starting treatment with Sunitinib or Pazopanib, and compare them to patients with localized or limited spread cancer not on these drugs. The goal is to find a simple blood test that helps doctors choose the best treatment for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which kidney cancer patients will benefit from anti-angiogenic drugs like Sunitinib or Pazopanib.
What could go wrong
This is a small, early-stage biomarker study with only 50 participants. It does not test a new treatment, so it may not lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Paoli Calmettes
Marseille, 13009, France